Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Hwang

Showing results (231-240 of 242) with videos related to

Pageof 25
Sort By:
British Journal of Cancer|October 28, 2015
A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancerS H Lim, T W Kim, Y S Hong, et al.
Oncotarget|November 8, 2017
A three gene immunohistochemical panel serves as an adjunct to clinical staging of patients with head and neck cancerChin-Ann J Ong, Nicholas B Shannon, Stefan Mueller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2021
Pan-cancer Transcriptomic Predictors of Perineural Invasion Improve Occult Histopathologic DetectionJimmy A Guo, Hannah I Hoffman, Stuti G Shroff, et al.
ESMO Open|September 21, 2024
Nationwide precision oncology pilot study: KOrean Precision Medicine Networking Group Study of MOlecular profiling-guided therapy based on genomic alterations in advanced solid tumors (KOSMOS) KCSG AL-20-05T-Y Kim, S Y Kim, J H Kim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 5, 2020
A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial<sup>☆</sup>S H Park, D H Lim, T S Sohn, et al.
Nature Communications|September 7, 2017
Phenotype-driven precision oncology as a guide for clinical decisions one patient at a timeShumei Chia, Joo-Leng Low, Xiaoqian Zhang, et al.
ESMO Open|September 18, 2025
Identifying predictive markers of head and neck squamous cell carcinoma in an umbrella trial (KCSG HN 15-16 TRIUMPH trial)S Hwang, M H Hong, S H Shin, et al.
Oral Oncology|October 22, 2020
Pairing a prognostic target with potential therapeutic strategy for head and neck cancerSze Min Lek, Ke Li, Qiu Xuan Tan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
Eight-signature classifier for prediction of nasopharyngeal [corrected] carcinoma survivalHai-Yun Wang, Bing-Yu Sun, Zhi-Hua Zhu, et al.
Chinese Journal of Cancer|May 6, 2016
A new prognostic histopathologic classification of nasopharyngeal carcinomaHai-Yun Wang, Yih-Leong Chang, Ka-Fai To, et al.
Pageof 25

Showing results (231-240 of 242) with videos related to

Sort By:
Pageof 25
British Journal of Cancer|October 28, 2015
A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancerS H Lim, T W Kim, Y S Hong, et al.
Oncotarget|November 8, 2017
A three gene immunohistochemical panel serves as an adjunct to clinical staging of patients with head and neck cancerChin-Ann J Ong, Nicholas B Shannon, Stefan Mueller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2021
Pan-cancer Transcriptomic Predictors of Perineural Invasion Improve Occult Histopathologic DetectionJimmy A Guo, Hannah I Hoffman, Stuti G Shroff, et al.
ESMO Open|September 21, 2024
Nationwide precision oncology pilot study: KOrean Precision Medicine Networking Group Study of MOlecular profiling-guided therapy based on genomic alterations in advanced solid tumors (KOSMOS) KCSG AL-20-05T-Y Kim, S Y Kim, J H Kim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 5, 2020
A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial<sup>☆</sup>S H Park, D H Lim, T S Sohn, et al.
Nature Communications|September 7, 2017
Phenotype-driven precision oncology as a guide for clinical decisions one patient at a timeShumei Chia, Joo-Leng Low, Xiaoqian Zhang, et al.
ESMO Open|September 18, 2025
Identifying predictive markers of head and neck squamous cell carcinoma in an umbrella trial (KCSG HN 15-16 TRIUMPH trial)S Hwang, M H Hong, S H Shin, et al.
Oral Oncology|October 22, 2020
Pairing a prognostic target with potential therapeutic strategy for head and neck cancerSze Min Lek, Ke Li, Qiu Xuan Tan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
Eight-signature classifier for prediction of nasopharyngeal [corrected] carcinoma survivalHai-Yun Wang, Bing-Yu Sun, Zhi-Hua Zhu, et al.
Chinese Journal of Cancer|May 6, 2016
A new prognostic histopathologic classification of nasopharyngeal carcinomaHai-Yun Wang, Yih-Leong Chang, Ka-Fai To, et al.
Pageof 25